Q4 2024 Earnings Call Transcript January 22, 2025 Johnson & Johnson beats earnings expectations. Reported EPS is $2.04, ...

The company's multiple myeloma franchise, which includes Carvykti, stands to contribute significantly to its growth in 2025.

Tagrisso and Imfinzi are projected to generate global sales of $8bn and $7bn, respectively, by 2030, according to GlobalData.

As Stelara biosimilars chip away at sales in Europe and off-brand rivals start to grace the stage in the U.S., Johnson & ...

The Lazcluze plus Rybrevant combination could challenge AstraZeneca’s standard-of-care Tagrisso in non-small cell lung cancer ...

Meanwhile, J&J has claimed EU approval for its combination of EGFRxMET bispecific antibody Rybrevant (amivantamab) with third ...

The European Commission (EC) has approved a Marketing Authorization (MA) for Lazcluze (lazertinib), in combination with ...

The European Commission (EC) has approved the marketing authorisation for LAZCLUZE (lazertinib) in combination with RYBREVANT ...

But a pair of treatments that launched in 2019 are already offsetting Humira's losses. Combined sales of Skyrizi, a psoriasis ...

Prince Harry's hotly anticipated lawsuit trial against a British tabloid publisher alleging it carried out unlawful ...

Johnson & Johnson (JNJ) announced that Health Canada has issued a Notice of Compliance for RYBREVANT (amivantamab for injection) in ...